Marie E. Lamont is responsible for the overall vision and operations of Inteliquet. With the goal of providing patients and physicians access to the latest and best treatment options and care available, she helps commercialize Inteliquet’s offerings of intelligent technology, insights, and services to improve the clinical trial process, research, and translational medicine.

With more than 25 years as a global biotech leader, Marie has significant commercial and operational expertise. She has held senior leadership positions in many areas focusing on corporate strategic planning and analytics, commercial operations, finance and accounting, patient services, and payer contracting and reimbursement. Prior to Inteliquet, Marie headed up an executive consulting and advisory firm for the life science and technology industries that advised companies on commercialization and integration planning, M&A support, and global market expansion.

Before her consultancy, Marie was President of the Patient Services Business at Dohmen Life Science Services (DLSS), which was subsequently sold and is now part of EVERSANA (a provider of global services to the life science industry). She directed all aspects of the unit and was responsible for improving the client and patient focus by shoring up the underlying infrastructure, as well as improving patient support and employee engagement. She also was heavily involved in the success of DLSS’s brand positioning, strategic road mapping, sales business development, and patient journey adoption, along with targeting analytics for key initiatives.

Prior to DLSS, Marie was Global Head of Business Strategy and Commercial Operations for Rare Disease at Sanofi Genzyme. She had stewardship for the $2.9B business where annual operating profit improved at a rate greater than revenue. As a member of the senior leadership team, she was tasked with decision analytics and support as well as bringing together disparate groups and functions into a cohesive, comprehensive global unit. While reestablishing a Rare Disease global strategy, she worked to align efforts with a range of functions, including R&D, Biologics Manufacturing, and Medical/Regulatory Affairs. She also help to lead humanitarian programs that provided free therapy for more than 1,100 patients suffering from rare diseases in emerging markets.

Prior to this position, she held several senior operational and finance roles. She took on the assignment of Vice President of Integration for Finance and Accounting following the Sanofi acquisition. Before this assignment, she was Vice President of Operations & Finance for the International Group where the business grew from $100M in 2002 to $2B at time of the Sanofi acquisition. She guided the operational strategy for the international infrastructure on a regional and country basis for the Oncology, Transplant, Renal, Biosurgery, and Rare Disease Business Units. Before this role, she directed Corporate Financial Planning & Analysis and Strategic Planning.

Marie holds a bachelor’s degree in Business from Saint Michael’s College, and attended Harvard Business School and Kellogg Executive Education programs. She lives in the St. Louis area.

“Early on, I was fortunate to work for a CEO who believed that when you treat patients and employees right, business success follows — and you can change the world. I believe this applies to every employee in any role whether patient facing or not.

“My grandfather passed due to lung cancer, so I saw how the cycle of disease progression and therapy can be a horrid emotional journey for everyone involved. When considering a new role, I evaluate whether I can make a difference to patients now or in the future. Since Inteliquet can harness the best data to rapidly identify and qualify patients for trials, we have a significant opportunity to benefit patients, improve health outcomes, and advance the standard of care in oncology and beyond.”

W. Jeffery Edenfield, MD brings to Inteliquet more than 25 years of expertise in all aspects of clinical oncology, including translational oncology research, cancer care and care delivery. As a strategic medical advisor, he works to enhance Inteliquet’s platform, so that it can contribute to improved outcomes through personalized treatment for patients needing access to clinical trials.

Dr. Edenfield is Medical Director at the Institute for Translational Oncology Research (ITOR) at Greenville Health System (GHS) Cancer Institute, which advances care on multiple levels, including facilitating pioneering research and clinical care delivery. He oversees phase I and first-in-human clinical trials for new cancer medications and manages its Biorepository Services.

Dr. Edenfield is board certified in Medical Oncology and Hematology. He is also certified in Hospice and Palliative Medicine. He has published numerous peer-reviewed articles and has been a national principal investigator for phase l, ll, and lll oncology trials. He is a member of the American Society of Clinical Oncology and is the Academic Vice Chair for Oncology in the Greenville Health System, where he is currently an Associate Professor in the Department of Medicine. His extensive experience in the application of genomic information on patient care has driven a focus on enabling patients with access to quality clinical trials.

Dr. Edenfield earned his Medical Degree from the University of Miami, Florida. He completed his internship, residency, and fellowship at Walter Reed Army Medical Center in Washington, D.C. Dr. Edenfield also completed a research fellowship in Hematologic Malignancy at Johns Hopkins University School of Medicine in Baltimore, Maryland. He completed his active duty service obligation, obtaining the rank of Major, as Chief of Oncology at Womack Army Medical Center in North Carolina.

 “I am hopeful about the many new treatments emerging for my patients. Every day there are new pathways of drug approval, which are accelerating the options for keeping them well. However, we are reaching only a small fraction of patients with respect to clinical trial enrollment. With hundreds of new drugs needing to be studied, innovative methods to inform physicians and match patients to these trials have never been more important. Doubling the number of adults who join oncology clinical trials from three percent to six percent would be a tremendous accomplishment, and Inteliquet is uniquely positioned to move us in that direction.”

Dr. Krenitsky is a recognized authority in global diagnostic and biotechnology operations with more than 20 years of senior leadership experience. He was Chief Operating Officer, and later Chief Commercial Officer of Foundation Medicine, a molecular information company dedicated to transforming cancer treatment through enhanced understanding of genomic changes that contribute to a patient’s unique cancer. He helped build the company to a successful IPO, followed by a $1.2B investment by Roche, leading to a full acquisition.

Previously, he served as President of Enzo Clinical Labs and instituted a strategic plan to launch numerous FDA-approved esoteric tests. He served as CEO at both BioServe Biotechnologies, a global biotechnology company, and Parkway Clinical Laboratories, a clinical diagnostic lab. He also has held senior-level positions with Genomics Collaborative, Inc., a clinical and genomics research company.

Dr. Krenitsky received a Bachelor of Science in Business Management from the University of Scranton and a Medical Degree from Jefferson Medical College, Philadelphia. He currently serves on the Board of Directors of several life science companies, including Lumicell, a technology leader developing systems to enable surgeons to see residual cancer cells in the cavity walls in real-time during surgery.

For more than three decades, Peter has strategically guided the growth and development of service firms supporting biopharma clinical research and commercialization. He joined Inteliquet to lead the expansion of our life sciences offerings as the need for efficiently developed oncology treatments becomes more critical in a rapidly changing healthcare environment. As Senior Vice President, Life Sciences, he leads the group responsible for the sale and delivery of the company’s solutions to pharmaceutical, biotechnology, contract research organizations, and other groups utilizing patient level data.

Prior to joining Inteliquet, Peter was co-founder and CEO of CRO Analytics, a provider of a cloud-based clinical trial performance system platform. Previous to that, Peter was Vice President and General Manager at the MAPI Group, where he helped lead the acquisition and integration of Registrat, Inc. in a transaction that created the largest global CRO exclusively devoted to post-marketing research.

He was also President of US Operations for the CRO Premier Research, where he led that group to its highest growth rates and profitability. Other senior roles include at SCIREX (US-focused CRO acquired by Premier), Galt Associates (drug safety and software services), MEDTAP International (health economics and outcomes), PAREXEL International (global CRO) and State & Federal Associates (market access services).

Peter holds a bachelor’s degree in Political Science from the University of Richmond and an MBA in Marketing from George Washington University. He has served as a Board member and adviser to several early-stage biopharma services companies. He is a regular lecturer at Drexel University’s LeBow College of Business MBA in Pharmaceutical Management program and industry conferences.

Kirk Junker is responsible for all aspects of software development and operations to create, test, deploy, and manage Inteliquet’s Clinical Consortium. He oversees teams of software engineers, operations engineers, and data engineers responsible for the production operations, which include matching patients for clinical trials and providing clinical trial feasibility assessment. He joined Inteliquet as Director of Engineering in 2011.

Kirk has more than 25 years of experience in all aspects of strategic technology solutions and architecture, design, development, implementation consulting services, and program management experience. He is familiar with solutions surrounding protected health information, de-identifying patient information, master patient index, and the integration of patient data systems for analytics. 

Kirk has expertise and leadership experience designing large, complex data warehouses and data integration solutions as well as commercial software products. He has designed genomics database solutions and worked with clinical informatics protocols in the biomedical industry. Prior to Inteliquet, Kirk founded Toscana Solutions, LLC, a software and consulting services company that used open source products to implement effective and affordable data warehouse, business intelligence, predictive analytics, data integration and data visualization solutions. Among the products he designed and developed were a predictive analytics solution for a large hospital to improve efficiency of scheduling; patient management and billing systems; and an online application that provided patients a genetic analysis of their cancer tissue from a genotype along with drug data and research to provide a recommended treatment plan.

Prior to Toscana Solutions, Kirk was a member of the senior management team for a leading-edge technical services firm managing the growth of a software services organization for up to 170 consultants and alliance partners. His responsibilities included all aspects of delivery operations, budgeting, business development, and engagement management. His previous work experience also includes the role Director of Innovation for the RDA Corporation, where he oversaw a portfolio of software development engagements, while also responsible for developing new products, services, and revenue generating opportunities. His past professional experience also included three years as an Application Developer for Arthur Andersen, LLP.

Kirk received his Bachelor of Science in business finance from Virginia Polytechnic Institute and State University in Blacksburg, Virginia. 

Jim Reddy has more than 28 years of experience overseeing clinical operations and analytics for medical practices and hospitals. He is passionate about the pursuit of meaningful data to improve patient outcomes, develop effective practice operations, and inform healthcare practice and policy.

As Vice President of Customer Engagement, Jim works to integrate Inteliquet’s software solutions into client workflows, increase utilization, and develop on-boarding processes for new clients. His department provides customer training, support, connects clients with clinical trial sponsors, and works with Inteliquet’s Life Sciences division to support Contract Research Organization (CRO) projects.

Before Inteliquet, Jim was Director of Information Systems at New England Cancer Specialists overseeing clinical operations for the 22-provider hematology/oncology practice. He oversaw development of their multi-system IT network; supervised all system integration, EMR development and training, data analysis, and reporting; and managed development and construction of two new medical office buildings. He assisted in the COME HOME project, a Medicare-funded project aimed at demonstrating improved outcomes at lower costs, and he was Data Custodian for the CMS-funded Oncology Care Model project.

Early on, Jim was involved in cardiology, as the Operations Director for Cardiovascular Consultants of Maine, a 24-physician cardiology group. He managed information systems, performed data analysis, developed an electronic patient record system, and implemented a clinical research division and a nuclear medicine department. Prior to this he was Non-invasive Cardiology Director at Maine Medical Center, where he managed a staff of 28 at the 600-bed teaching hospital. He was responsible for staffing and operations of the Echocardiography and EKG labs, maintaining the division’s operating and capital budgets, writing policy and procedures for each department, and training echocardiographic technologists.

Jim began his career as an Echocardiographic Technologist, performing all types of procedures (e.g., transthoracic, adult, pediatric, and transesophageal). He holds a degree in Cardiovascular Technology from Barna College.

“I lost my sister to cancer, and one of my best friends has been living with brain cancer for the past decade. It’s hard to watch people suffering, especially when you feel helpless to do anything about it. It pushed me into healthcare, where I started out in cardiology and then moved to oncology. It is my way of helping out and doing what I can.“

Linda Andrews leads the Clinical Engagement Team, which provides education, training, and ongoing support on Inteliquet’s platform for clinicians, nurses, CROs, clinical trial design teams, and research staff. With 30+ years of nursing, clinical research, training, and leadership experience, Linda is an expert in best-practice techniques and strategies that accelerate clinical trial enrollment.

Before Inteliquet, Linda worked at Novartis Pharmaceuticals as a Regional Manager for their Patient and Specialty Services Division, managing nurse educators. Her responsibilities included streamlining on-boarding, building relationships with National Key Opinion Leaders, providing patient education and clinical resource support for physicians and office staff, and acting as the program liaison for sales, marketing, and managed care. In her first year, she decreased the first-start day from 104 days to 22 days, a 79% efficiency improvement. Two years later she, decreased the national first-start days from 122 to 17 days, an 84% improvement. Linda was also a key player in increasing the first-time managed market approvals from 15% to 95%.

Prior to Novartis, Linda was Director of Clinical Studies at VASCUTEK, a subsidiary of Terumo Corporation, and manufacturer of vascular and cardiovascular products. In addition to managing U.S. and Canadian clinical trials with budgets exceeding $5M, she was a medical and scientific resource for feasibility studies, leading clinical operations and project management for 510k and Class III IDE medical device studies. She oversaw research associates and field medical device clinical specialists, and supported education and training of all internal/external customers of the clinical trial process. Her work also involved managing FDA reporting requirements, including endpoint and pre-IDE submissions.

Prior to VASCUTEK, Linda was Clinical Research Manager/Lead Coordinator and Nurse Educator at the Jobst Vascular Institute, part of the ProMedica Health System in Toledo, Ohio. She managed clinical research staff for trials of bleeding disorders, cardiovascular, endovascular, peripheral vascular disease, and wound care ranging from medical device class III and pharmaceutical phase I-IV trials. She also was responsible for financial and budgetary reporting for $1-5M studies as well as regulatory management, investigational study site selection, and site/sponsor relationships.

Linda also was an Investigation Review Board (IRB) reviewer and a ProMedica Health board member. Earlier, she worked in the Adult Medicine and Specialty Clinic as an Ambulatory Clinic Nurse and Educator, where she developed, implemented, and tracked department and patient educational materials. She educated staff on a range of subjects from orientation and equipment updates to JCAHO and HIPAA training. She also handled patient Inclusion/Exclusion for selected cardiovascular and oncology research programs and conducted patient education for diabetic and hepatitis C injection training. Linda began her career at the Toledo Hospital, where she spent 18 years in RN roles in cardiovascular recovery and stress testing, coronary intensive care, cardiac rehabilitation, neurology intensive care, and inpatient pain management.

Linda holds a master’s degree (summa cum laude) in the Science of Nursing from Walden University in Minneapolis, Minn. She also has a bachelor’s degree (summa cum laude) in Education and an associate degree in Nursing both from the University of Toledo. She holds three certifications in clinical research and has been published in the Journal of Vascular Nursing, Journal of Vascular Surgery, and Journal of Internal Medicine.

“I’ve wanted to be a nurse since I was five years old, when I told my grandmother I would grow up and take care of her. Years later, I helped care for her during her last days at home, when she went into Hospice care. Cancer has affected many in my family and close friends, both young and old. It is urgent that everyone have access to clinical trials when facing a cancer diagnosis or another debilitating disease. I work daily to help healthcare providers and their staffs find alternative treatment options when the time-to-treatment counts.”

Dorit Baxter is responsible all marketing and lead-generation efforts for Inteliquet. She has nearly 20 years of experience leading global marketing, communications and sales enablement functions for a range of healthcare, health insurance, and technology companies.

Prior to Inteliquet, Dorit was Senior Vice President of Marketing at Remedy Partners, the largest Convener under Medicare’s Bundle Payments for Care Improvement (BPCI) program. She was charged with driving brand awareness and building a pipeline of leads for the organization. She also worked on strategies for expansion into the commercial sector.

Before Remedy Partners, Dorit was the Director of Brand Strategy and Corporate Marketing for Nanthealth, a personalized healthcare company, where she led all marketing communications and press relations for payer, provider, and patient audiences. She also managed all channel and influencer marketing activities, including national and regional tradeshows and key client events.

Dorit also worked at Blue Cross & Blue Shield of Rhode Island with a focus on marketing strategies for the Medicare Advantage market, as well as customer experience. Early on in her career, she led global marketing communications and sales enablement for IBM’s small and mid-sized business customer segment, creating customer loyalty and retention programs, as well as business partner campaigns, training programs, and sales resources.

Dorit holds Bachelor of Arts degrees in English and Psychology from the University of Maryland and studied Global Strategy and Management at The Peter Drucker-Masatoshi Ito School of Management, Claremont Graduate University. She speaks fluent German.

“Nothing is more rewarding than building awareness for real solutions that have the potential to solve for cancers or other critical illnesses. I joined Inteliquet after I learned how their technology, insights and services can help advance the delivery of new, potentially life-saving treatments. I work every day to contribute in some small way so that patients can live longer and have more time with loved ones. I do it for Oma, Beverly, Martie, Leslie, Cub, Colleen, and Deb.”

Bob Robbins leads all aspects of sales and sales management at Inteliquet and has more than 30 years of experience building and leading multi-million-dollar programs for a range of clinical trial, health sciences, and genomics companies. He has consistently built and maintained world-class organizations — developing new markets, meeting quotas, and building strong pipelines. His skill set includes developing sales channels, programs, and sales methods for new lines of business in shifting markets.

Prior to Inteliquet, Bob was Vice President of Business Development at Agile Edge Health, where he developed a pipeline of qualified business leads in academic medical centers, regional health networks, and hospitals for multiple lines of business. Before Agile, Bob was with Oracle Health Sciences (OHS) where he developed a $23M pipeline for OHS’s enterprise analytics and translational research solutions and sold Oracle’s Translational Research platform to several major Academic Medical Centers.

As Vice President of Sales Programs at Eclipsys Corporation, a computer software company, Bob was responsible for all sales programs, education, sales methodology, CRM integration, forecasting, and competitive analysis. He also worked to secure an agreement with the Voluntary Hospital Association (VHA) in Dallas, which increased clinical sales by $45M its first year. As President of the Southeast and Southwest Regions, he managed a $56M book of business on a margin basis.

Bob also was Vice President of Strategic Sales for Siemens Medical Solutions, where he led efforts for its $27M start-up clinical trials operations. Early in his career, Bob founded and was COO of Atlantic Physician Systems, Inc., where he improved physician reimbursement by 11-40 percent, expanded membership from 195 to 500 physicians, and managed partially at-risk managed care negotiations for the entire network.

Bob holds a Bachelor of Science in Health Planning and Administration from Pennsylvania State University.

“I saw joining Inteliquet as an opportunity to join a world-class company at a major inflection point in clinical research and precision medicine.”

Nate Sanders provides financial guidance and is responsible for all finance, accounting, and financial planning and analysis for Inteliquet. Nate joined in 2010 to develop Inteliquet’s financial infrastructure and systems for forecasting, budgeting, and reporting. He was involved in helping secure three rounds of significant equity financing as well as a grant from the National Science Foundation through Small Business Innovation Research (SBIR) program.

He has more than 28 years of experience in international finance, mergers and acquisitions, corporate integration, treasury and risk management, and strategic/operational business planning. Nate has taken companies from IPO through to commercialization. He has directed the growth of both public and private technology entities, created worldwide FP&A departments, and managed integrations for many M&A transactions totaling $200M+. He also has developed and mentored financial teams.

Prior to Inteliquet, Nate was Vice President of Finance for Pattern Insight, Inc., a data analysis company, where he was responsible for all aspects of finance, accounting, HR, tax, international tax structures, and capital and financial reporting for the consolidated U.S. parent and its China subsidiary. He was chosen by the president and CEO to assist with commercializing and launching the company’s first group of software analysis tools.

Previously, he was Vice President of Finance for Codefast, Inc., a provider of automation tools for software developers, where his efforts lead to the successful closure of $9M in VC funding. He was responsible for finance, HR, tax, revenue recognition policies, and financial modeling and reporting for U.S. parent and its Canadian subsidiary.

Prior to Codefast, Nate held several financial and treasury consultant positions and held responsibilities from budgeting and forecasting to cash management and developing FP&A departments. He began his career at Vanstar, a $3B computer reseller with 3,000+ employees, as a manager of Treasury operations where he provided internal reporting and analysis of franchise operations comprised of 250+ franchisees. He was promoted into Treasury to streamline its operations.

Nate holds a Bachelor of Science degree in finance from San Jose State University and lives in the San Jose area.

“It’s exciting to be with a company that has a direct impact on the health of individuals. I lost a good friend to cancer and have family members who battled — and who are battling — cancer. Inteliquet can have meaningful effects on patients when they need it most. That is what gets me out of bed and keeps me coming in to work every day.”

As the Controller, Aaron Aylesworth is responsible for overseeing the quality of accounting and financial reporting for Inteliquet. He has expertise in financial reporting and tax compliance, assists in strategic financial planning, and manages all of Inteliquet’s assets and liabilities.

Prior to Inteliquet, Aaron was a Manager for Tax Services at Stratagem, a Coloradobased CPA and consulting firm, where he was responsible for large and complex tax projects for entities and high net-worth individuals, as well as tax planning and research. Before Strategem, Aaron was at Arrone Appel, LLC, where he was in charge of controller services and solely responsible for all of the firm’s tax projects. He modernized the firm’s accounting processes, resulting in faster turnaround times for all client financial reporting.

Before Arrone Appel, Aaron was a Manager at Petrinovich Pugh and Company, LLP, a San Jose, Calif.-based, full-service accounting firm that provided planning, consulting and compliance services to small and medium-sized, privately held companies. He led controller services and monthly accounting along with financial statement preparation for multiple clients in the technology industry including software and hardware companies. He led the firm’s tax committee and consulted with clients on issues relating to software revenue recognition. He also worked with clients to implement the new ASC 606/IFRS 15 standard for revenue recognition.

Aaron holds a Bachelor of Science in Business Administration, with a concentration in Accounting, from San Jose State University. He is a Certified Public Accountant in Colorado and California.

“I lost my Mom quickly to cancer in 2014, so the company’s focus and mission are personal; it is an epidemic that affects everyone. Our CEO says she hates cancer in her email signature, and so do I. It’s great to work with people who are dedicated to meaningful work and passionate about beating this disease.”